Bacteria-instructed B cells cross-prime naïve CD8+ T cells triggering effective cytotoxic responses.

In addition to triggering humoral responses, conventional B cells have been described in vitro to cross-present exogenous antigens activating naïve CD8+ T cells. Nevertheless, the way B cells capture these exogenous antigens and the physiological roles of B cell-mediated cross-presentation remain po...

ver descrição completa

Detalhes bibliográficos
Autores: García-Ferreras, Raquel, Osuna-Pérez, Jesús, Ramírez-Santiago, Guillermo, Méndez-Pérez, Almudena, Acosta-Moreno, Andrés M, Del Campo, Lara, Gómez-Sánchez, María J, Iborra, Marta, Herrero-Fernández, Beatriz, González-Granado, José M, Sánchez-Madrid, Francisco, Carrasco, Yolanda R, Boya, Patricia, Martínez-Martín, Nuria, Veiga, Esteban
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16425
Acesso em linha:http://hdl.handle.net/20.500.12105/16425
Access Level:acceso abierto
Palavra-chave:CD8-Positive T-Lymphocytes
Dendritic Cells
Antigen Presentation
Cross-Priming
Antigens, Bacterial
Descrição
Resumo:In addition to triggering humoral responses, conventional B cells have been described in vitro to cross-present exogenous antigens activating naïve CD8+ T cells. Nevertheless, the way B cells capture these exogenous antigens and the physiological roles of B cell-mediated cross-presentation remain poorly explored. Here, we show that B cells capture bacteria by trans-phagocytosis from previously infected dendritic cells (DC) when they are in close contact. Bacterial encounter "instructs" the B cells to acquire antigen cross-presentation abilities, in a process that involves autophagy. Bacteria-instructed B cells, henceforth referred to as BacB cells, rapidly degrade phagocytosed bacteria, process bacterial antigens and cross-prime naïve CD8+ T cells which differentiate into specific cytotoxic cells that efficiently control bacterial infections. Moreover, a proof-of-concept experiment shows that BacB cells that have captured bacteria expressing tumor antigens could be useful as novel cellular immunotherapies against cancer.